#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-10	Functional	_
1-2	11-23	connectivity	_
1-3	24-26	of	_
1-4	27-30	the	_
1-5	31-39	striatum	_
1-6	40-42	in	_
1-7	43-56	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-8	57-60	and	_
1-9	61-70	psychotic	_
1-10	71-78	bipolar	_
1-11	79-87	disorder	_
1-12	88-98	Background	_
1-13	99-100	:	_
1-14	101-104	The	_
1-15	105-113	striatum	_
1-16	114-116	is	_
1-17	117-125	abnormal	_
1-18	126-128	in	_
1-19	129-142	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-20	143-144	,	_
1-21	145-148	and	_
1-22	149-157	possibly	_
1-23	158-168	represents	_
1-24	169-170	a	_
1-25	171-177	common	_
1-26	178-193	neurobiological	_
1-27	194-203	mechanism	_
1-28	204-214	underlying	_
1-29	215-224	psychotic	_
1-30	225-234	disorders	_
1-31	235-236	.	_

2-1	237-250	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-2	251-255	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-3	256-257	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-4	258-265	RS-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-5	266-267	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-6	268-275	studies	_
2-7	276-280	have	_
2-8	281-284	not	_
2-9	285-292	reached	_
2-10	293-294	a	_
2-11	295-304	consensus	_
2-12	305-314	regarding	_
2-13	315-323	striatal	_
2-14	324-339	dysconnectivity	_
2-15	340-342	in	_
2-16	343-356	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-17	357-358	,	_
2-18	359-367	although	_
2-19	368-373	these	_
2-20	374-381	studies	_
2-21	382-391	generally	_
2-22	392-396	find	_
2-23	397-405	impaired	_
2-24	406-421	fronto-parietal	_
2-25	422-425	and	_
2-26	426-434	salience	_
2-27	435-442	network	_
2-28	443-455	connectivity	_
2-29	456-457	.	_

3-1	458-461	The	_
3-2	462-466	goal	_
3-3	467-469	of	_
3-4	470-473	the	_
3-5	474-481	current	_
3-6	482-487	study	_
3-7	488-491	was	_
3-8	492-494	to	_
3-9	495-502	clarify	_
3-10	503-506	the	_
3-11	507-514	pattern	_
3-12	515-517	of	_
3-13	518-534	cortico-striatal	_
3-14	535-547	connectivity	_
3-15	548-549	,	_
3-16	550-559	including	_
3-17	560-567	whether	_
3-18	568-584	cortico-striatal	_
3-19	585-600	dysconnectivity	_
3-20	601-603	is	_
3-21	604-619	transdiagnostic	_
3-22	620-623	and	_
3-23	624-631	extends	_
3-24	632-636	into	_
3-25	637-646	psychotic	_
3-26	647-654	bipolar	_
3-27	655-663	disorder	_
3-28	664-665	.	_

4-1	666-673	Methods	_
4-2	674-675	:	_
4-3	676-678	We	_
4-4	679-687	examined	_
4-5	688-704	cortico-striatal	_
4-6	705-715	functional	_
4-7	716-728	connectivity	_
4-8	729-731	in	_
4-9	732-734	60	_
4-10	735-742	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-11	743-751	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-12	752-755	and	_
4-13	756-759	117	_
4-14	760-771	individuals	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
4-15	772-776	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
4-16	777-786	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
4-17	787-788	,	_
4-18	789-798	including	_
4-19	799-801	77	_
4-20	802-806	with	_
4-21	807-808	a	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
4-22	809-822	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
4-23	823-831	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
4-24	832-839	illness	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
4-25	840-843	and	_
4-26	844-846	40	_
4-27	847-851	with	_
4-28	852-861	psychotic	_
4-29	862-869	bipolar	_
4-30	870-878	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
4-31	879-880	.	_

5-1	881-883	We	_
5-2	884-893	conducted	_
5-3	894-898	both	_
5-4	899-900	a	_
5-5	901-909	cortical	_
5-6	910-920	seed-based	_
5-7	921-939	region-of-interest	_
5-8	940-941	(	_
5-9	942-945	ROI	_
5-10	946-947	)	_
5-11	948-956	analysis	_
5-12	957-961	with	_
5-13	962-971	follow-up	_
5-14	972-982	voxel-wise	_
5-15	983-991	analysis	_
5-16	992-995	for	_
5-17	996-999	any	_
5-18	1000-1011	significant	_
5-19	1012-1019	results	_
5-20	1020-1021	.	_

6-1	1022-1029	Further	_
6-2	1030-1031	,	_
6-3	1032-1033	a	_
6-4	1034-1042	striatum	_
6-5	1043-1053	seed-based	_
6-6	1054-1062	analysis	_
6-7	1063-1066	was	_
6-8	1067-1076	conducted	_
6-9	1077-1079	to	_
6-10	1080-1087	examine	_
6-11	1088-1093	group	_
6-12	1094-1105	differences	_
6-13	1106-1108	in	_
6-14	1109-1121	connectivity	_
6-15	1122-1129	between	_
6-16	1130-1133	the	_
6-17	1134-1142	striatum	_
6-18	1143-1146	and	_
6-19	1147-1150	the	_
6-20	1151-1156	whole	_
6-21	1157-1163	cortex	_
6-22	1164-1165	.	_

7-1	1166-1173	Results	_
7-2	1174-1175	:	_
7-3	1176-1184	Cortical	_
7-4	1185-1188	ROI	_
7-5	1189-1197	analysis	_
7-6	1198-1207	indicated	_
7-7	1208-1212	that	_
7-8	1213-1220	overall	_
7-9	1221-1233	connectivity	_
7-10	1234-1236	of	_
7-11	1237-1240	the	_
7-12	1241-1249	salience	_
7-13	1250-1257	network	_
7-14	1258-1262	with	_
7-15	1263-1266	the	_
7-16	1267-1275	striatum	_
7-17	1276-1279	was	_
7-18	1280-1287	reduced	_
7-19	1288-1290	in	_
7-20	1291-1300	psychotic	_
7-21	1301-1310	disorders	_
7-22	1311-1312	,	_
7-23	1313-1318	which	_
7-24	1319-1328	follow-up	_
7-25	1329-1339	voxel-wise	_
7-26	1340-1348	analysis	_
7-27	1349-1358	localized	_
7-28	1359-1361	to	_
7-29	1362-1365	the	_
7-30	1366-1370	left	_
7-31	1371-1378	putamen	_
7-32	1379-1380	.	_

8-1	1381-1389	Striatum	_
8-2	1390-1400	seed-based	_
8-3	1401-1409	analyses	_
8-4	1410-1416	showed	_
8-5	1417-1424	reduced	_
8-6	1425-1432	ventral	_
8-7	1433-1440	rostral	_
8-8	1441-1448	putamen	_
8-9	1449-1461	connectivity	_
8-10	1462-1466	with	_
8-11	1467-1470	the	_
8-12	1471-1479	salience	_
8-13	1480-1487	network	_
8-14	1488-1495	portion	_
8-15	1496-1498	of	_
8-16	1499-1502	the	_
8-17	1503-1509	medial	_
8-18	1510-1513	PFC	_
8-19	1514-1516	in	_
8-20	1517-1521	both	_
8-21	1522-1535	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-22	1536-1539	and	_
8-23	1540-1549	psychotic	_
8-24	1550-1557	bipolar	_
8-25	1558-1567	disorders	_
8-26	1568-1569	.	_

9-1	1570-1581	Conclusions	_
9-2	1582-1583	:	_
9-3	1584-1587	The	_
9-4	1588-1595	current	_
9-5	1596-1601	study	_
9-6	1602-1607	found	_
9-7	1608-1616	evidence	_
9-8	1617-1619	of	_
9-9	1620-1635	transdiagnostic	_
9-10	1636-1652	cortico-striatal	_
9-11	1653-1668	dysconnectivity	_
9-12	1669-1671	in	_
9-13	1672-1676	both	_
9-14	1677-1690	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-15	1691-1694	and	_
9-16	1695-1704	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
9-17	1705-1712	bipolar	_
9-18	1713-1721	disorder	_
9-19	1722-1723	,	_
9-20	1724-1733	including	_
9-21	1734-1741	reduced	_
9-22	1742-1750	salience	_
9-23	1751-1758	network	_
9-24	1759-1771	connectivity	_
9-25	1772-1773	,	_
9-26	1774-1776	as	_
9-27	1777-1781	well	_
9-28	1782-1784	as	_
9-29	1785-1792	reduced	_
9-30	1793-1805	connectivity	_
9-31	1806-1813	between	_
9-32	1814-1817	the	_
9-33	1818-1825	putamen	_
9-34	1826-1829	and	_
9-35	1830-1833	the	_
9-36	1834-1840	medial	_
9-37	1841-1844	PFC	_
9-38	1845-1846	.	_

10-1	1847-1854	Overall	_
10-2	1855-1856	,	_
10-3	1857-1860	the	_
10-4	1861-1868	current	_
10-5	1869-1874	study	_
10-6	1875-1881	points	_
10-7	1882-1884	to	_
10-8	1885-1888	the	_
10-9	1889-1897	relative	_
10-10	1898-1908	importance	_
10-11	1909-1911	of	_
10-12	1912-1920	salience	_
10-13	1921-1928	network	_
10-14	1929-1946	hypo-connectivity	_
10-15	1947-1949	in	_
10-16	1950-1959	psychotic	_
10-17	1960-1969	disorders	_
10-18	1970-1971	.	_

11-1	1972-1979	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
11-2	1980-1985	Study	_
11-3	1986-1998	Participants	_
11-4	1999-2002	193	_
11-5	2003-2014	individuals	_
11-6	2015-2016	(	_
11-7	2017-2019	61	_
11-8	2020-2027	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-9	2028-2036	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-10	2037-2038	,	_
11-11	2039-2042	132	_
11-12	2043-2054	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
11-13	2055-2059	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
11-14	2060-2061	a	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
11-15	2062-2071	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
11-16	2072-2080	disorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
11-17	2081-2082	)	_
11-18	2083-2087	that	_
11-19	2088-2100	participated	_
11-20	2101-2103	in	_
11-21	2104-2106	an	_
11-22	2107-2115	on-going	_
11-23	2116-2127	NIMH-funded	_
11-24	2128-2133	study	_
11-25	2134-2136	on	_
11-26	2137-2142	brain	_
11-27	2143-2155	connectivity	_
11-28	2156-2158	in	_
11-29	2159-2168	psychotic	_
11-30	2169-2178	disorders	_
11-31	2179-2183	were	_
11-32	2184-2193	initially	_
11-33	2194-2202	screened	_
11-34	2203-2206	for	_
11-35	2207-2216	inclusion	_
11-36	2217-2219	in	_
11-37	2220-2224	this	_
11-38	2225-2238	investigation	_
11-39	2239-2240	.	_

12-1	2241-2243	16	_
12-2	2244-2256	participants	_
12-3	2257-2260	did	_
12-4	2261-2264	not	_
12-5	2265-2269	meet	_
12-6	2270-2273	our	_
12-7	2274-2286	neuroimaging	_
12-8	2287-2294	quality	_
12-9	2295-2304	assurance	_
12-10	2305-2306	(	_
12-11	2307-2309	QA	_
12-12	2310-2311	)	_
12-13	2312-2322	procedures	_
12-14	2323-2332	described	_
12-15	2333-2338	below	_
12-16	2339-2340	.	_

13-1	2341-2345	Thus	_
13-2	2346-2347	,	_
13-3	2348-2351	the	_
13-4	2352-2357	final	_
13-5	2358-2364	cohort	_
13-6	2365-2374	consisted	_
13-7	2375-2377	of	_
13-8	2378-2381	177	_
13-9	2382-2387	study	_
13-10	2388-2400	participants	_
13-11	2401-2402	:	_
13-12	2403-2405	60	_
13-13	2406-2413	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-14	2414-2425	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-15	2426-2427	,	_
13-16	2428-2430	77	_
13-17	2431-2442	individuals	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-18	2443-2447	with	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-19	2448-2449	a	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-20	2450-2463	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-21	2464-2472	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-22	2473-2480	illness	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-23	2481-2482	(	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
13-24	2483-2486	i.e	_
13-25	2487-2488	.	_

14-1	2489-2502	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-2	2503-2504	,	_
14-3	2505-2520	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
14-4	2521-2522	,	_
14-5	2523-2526	and	_
14-6	2527-2543	schizophreniform	http://maven.renci.org/NeuroBridge/neurobridge#SchizophreniformDisorder
14-7	2544-2552	disorder	http://maven.renci.org/NeuroBridge/neurobridge#SchizophreniformDisorder
14-8	2553-2554	)	_
14-9	2555-2556	,	_
14-10	2557-2560	and	_
14-11	2561-2563	40	_
14-12	2564-2575	individuals	_
14-13	2576-2580	with	_
14-14	2581-2588	bipolar	_
14-15	2589-2597	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
14-16	2598-2602	with	_
14-17	2603-2612	psychotic	_
14-18	2613-2621	features	_
14-19	2622-2623	(	_
14-20	2624-2627	i.e	_
14-21	2628-2629	.	_

15-1	2630-2639	psychotic	_
15-2	2640-2647	bipolar	_
15-3	2648-2656	disorder	_
15-4	2657-2658	)	_
15-5	2659-2660	.	_

16-1	2661-2672	Demographic	_
16-2	2673-2677	data	_
16-3	2678-2681	are	_
16-4	2682-2691	presented	_
16-5	2692-2694	in	_
16-6	2695-2700	Table	_
16-7	2701-2702	1	_
16-8	2703-2704	.	_

17-1	2705-2713	Patients	_
17-2	2714-2718	were	_
17-3	2719-2728	recruited	_
17-4	2729-2736	through	_
17-5	2737-2740	the	_
17-6	2741-2750	Psychotic	_
17-7	2751-2760	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
17-8	2761-2768	Program	_
17-9	2769-2775	within	_
17-10	2776-2779	the	_
17-11	2780-2790	Department	_
17-12	2791-2793	of	_
17-13	2794-2804	Psychiatry	_
17-14	2805-2808	and	_
17-15	2809-2819	Behavioral	_
17-16	2820-2828	Sciences	_
17-17	2829-2831	at	_
17-18	2832-2842	Vanderbilt	_
17-19	2843-2853	University	_
17-20	2854-2861	Medical	_
17-21	2862-2868	Center	_
17-22	2869-2870	(	_
17-23	2871-2875	VUMC	_
17-24	2876-2877	)	_
17-25	2878-2879	.	_

18-1	2880-2887	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-2	2888-2899	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-3	2900-2904	were	_
18-4	2905-2914	recruited	_
18-5	2915-2919	from	_
18-6	2920-2929	Nashville	_
18-7	2930-2933	and	_
18-8	2934-2945	surrounding	_
18-9	2946-2950	area	_
18-10	2951-2954	via	_
18-11	2955-2968	advertisement	_
18-12	2969-2972	and	_
18-13	2973-2986	word-of-mouth	_
18-14	2987-2988	.	_

19-1	2989-2993	This	_
19-2	2994-2999	study	_
19-3	3000-3003	was	_
19-4	3004-3012	approved	_
19-5	3013-3015	by	_
19-6	3016-3019	the	_
19-7	3020-3030	Vanderbilt	_
19-8	3031-3041	University	_
19-9	3042-3055	Institutional	_
19-10	3056-3062	Review	_
19-11	3063-3068	Board	_
19-12	3069-3070	.	_

20-1	3071-3074	All	_
20-2	3075-3080	study	_
20-3	3081-3093	participants	_
20-4	3094-3102	provided	_
20-5	3103-3110	written	_
20-6	3111-3119	informed	_
20-7	3120-3127	consent	_
20-8	3128-3133	prior	_
20-9	3134-3136	to	_
20-10	3137-3150	participating	_
20-11	3151-3152	.	_

21-1	3153-3164	Psychiatric	_
21-2	3165-3174	diagnoses	_
21-3	3175-3179	were	_
21-4	3180-3189	confirmed	_
21-5	3190-3192	in	_
21-6	3193-3201	patients	_
21-7	3202-3205	and	_
21-8	3206-3211	ruled	_
21-9	3212-3215	out	_
21-10	3216-3218	in	_
21-11	3219-3226	healthy	_
21-12	3227-3235	subjects	_
21-13	3236-3241	using	_
21-14	3242-3245	the	_
21-15	3246-3256	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
21-16	3257-3265	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
21-17	3266-3275	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
21-18	3276-3279	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
21-19	3280-3290	Diagnosing	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
21-20	3291-3297	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
21-21	3298-3307	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
21-22	3308-3309	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
21-23	3310-3314	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
21-24	3315-3316	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
21-25	3317-3318	.	_

22-1	3319-3327	Patients	_
22-2	3328-3332	were	_
22-3	3333-3340	further	_
22-4	3341-3349	assessed	_
22-5	3350-3354	with	_
22-6	3355-3358	the	_
22-7	3359-3367	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-8	3368-3371	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-9	3372-3380	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-10	3381-3389	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-11	3390-3395	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-12	3396-3397	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-13	3398-3403	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-14	3404-3405	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-15	3406-3407	,	_
22-16	3408-3413	Young	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
22-17	3414-3419	Mania	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
22-18	3420-3426	Rating	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
22-19	3427-3432	Scale	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
22-20	3433-3434	(	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
22-21	3435-3439	YMRS	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
22-22	3440-3441	)	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
22-23	3442-3443	,	_
22-24	3444-3447	and	_
22-25	3448-3456	Hamilton	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
22-26	3457-3467	Depression	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
22-27	3468-3473	Scale	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
22-28	3474-3475	(	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
22-29	3476-3481	HAM-D	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
22-30	3482-3483	)	http://maven.renci.org/NeuroBridge/neurobridge#CalgaryDepressionScale
22-31	3484-3486	to	_
22-32	3487-3495	quantify	_
22-33	3496-3504	severity	_
22-34	3505-3507	of	_
22-35	3508-3517	psychotic	_
22-36	3518-3519	,	_
22-37	3520-3525	mania	_
22-38	3526-3527	,	_
22-39	3528-3531	and	_
22-40	3532-3542	depression	_
22-41	3543-3551	symptoms	_
22-42	3552-3553	,	_
22-43	3554-3566	respectively	_
22-44	3567-3568	.	_

23-1	3569-3572	The	_
23-2	3573-3581	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
23-3	3582-3586	Test	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
23-4	3587-3589	of	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
23-5	3590-3595	Adult	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
23-6	3596-3603	Reading	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
23-7	3604-3605	(	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
23-8	3606-3610	WTAR	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
23-9	3611-3612	)	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
23-10	3613-3616	was	_
23-11	3617-3629	administered	_
23-12	3630-3632	to	_
23-13	3633-3636	all	_
23-14	3637-3645	subjects	_
23-15	3646-3648	to	_
23-16	3649-3656	provide	_
23-17	3657-3659	an	_
23-18	3660-3668	estimate	_
23-19	3669-3671	of	_
23-20	3672-3682	pre-morbid	_
23-21	3683-3692	intellect	_
23-22	3693-3694	.	_

24-1	3695-3700	Study	_
24-2	3701-3713	participants	_
24-3	3714-3718	also	_
24-4	3719-3728	completed	_
24-5	3729-3732	the	_
24-6	3733-3739	Screen	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
24-7	3740-3743	for	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
24-8	3744-3753	Cognitive	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
24-9	3754-3764	Impairment	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
24-10	3765-3767	in	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
24-11	3768-3778	Psychiatry	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
24-12	3779-3780	(	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
24-13	3781-3785	SCIP	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
24-14	3786-3787	)	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
24-15	3788-3789	,	_
24-16	3790-3791	a	_
24-17	3792-3797	brief	_
24-18	3798-3816	neuropsychological	_
24-19	3817-3824	battery	_
24-20	3825-3829	that	_
24-21	3830-3838	includes	_
24-22	3839-3840	a	_
24-23	3841-3845	word	_
24-24	3846-3850	list	_
24-25	3851-3859	learning	_
24-26	3860-3864	test	_
24-27	3865-3867	of	_
24-28	3868-3874	verbal	_
24-29	3875-3881	memory	_
24-30	3882-3883	,	_
24-31	3884-3885	a	_
24-32	3886-3893	version	_
24-33	3894-3896	of	_
24-34	3897-3900	the	_
24-35	3901-3909	Auditory	_
24-36	3910-3919	Consonant	_
24-37	3920-3928	Trigrams	http://maven.renci.org/NeuroBridge/neurobridge#Actigraph
24-38	3929-3933	test	_
24-39	3934-3936	of	_
24-40	3937-3944	working	_
24-41	3945-3951	memory	_
24-42	3952-3953	,	_
24-43	3954-3962	phonemic	_
24-44	3963-3969	verbal	_
24-45	3970-3977	fluency	_
24-46	3978-3979	,	_
24-47	3980-3983	and	_
24-48	3984-3985	a	_
24-49	3986-3992	coding	_
24-50	3993-3997	test	_
24-51	3998-4000	of	_
24-52	4001-4011	processing	_
24-53	4012-4017	speed	_
24-54	4018-4019	.	_

25-1	4020-4024	SCIP	_
25-2	4025-4033	sub-test	_
25-3	4034-4037	raw	_
25-4	4038-4044	scores	_
25-5	4045-4049	were	_
25-6	4050-4059	converted	_
25-7	4060-4062	to	_
25-8	4063-4071	z-scores	_
25-9	4072-4077	using	_
25-10	4078-4088	previously	_
25-11	4089-4098	published	_
25-12	4099-4108	normative	_
25-13	4109-4113	data	_
25-14	4114-4117	and	_
25-15	4118-4126	averaged	_
25-16	4127-4129	to	_
25-17	4130-4136	create	_
25-18	4137-4138	a	_
25-19	4139-4140	“	_
25-20	4141-4150	composite	_
25-21	4151-4152	”	_
25-22	4153-4160	z-score	_
25-23	4161-4163	of	_
25-24	4164-4171	overall	_
25-25	4172-4181	cognitive	_
25-26	4182-4193	functioning	_
25-27	4194-4195	.	_

26-1	4196-4205	Exclusion	_
26-2	4206-4214	criteria	_
26-3	4215-4223	included	_
26-4	4224-4227	age	_
26-5	4228-4232	less	_
26-6	4233-4237	than	_
26-7	4238-4240	16	_
26-8	4241-4243	or	_
26-9	4244-4251	greater	_
26-10	4252-4256	than	_
26-11	4257-4259	55	_
26-12	4260-4261	;	_
26-13	4262-4271	estimated	_
26-14	4272-4282	pre-morbid	_
26-15	4283-4285	IQ	_
26-16	4286-4290	less	_
26-17	4291-4295	than	_
26-18	4296-4298	70	_
26-19	4299-4300	;	_
26-20	4301-4309	presence	_
26-21	4310-4312	of	_
26-22	4313-4314	a	_
26-23	4315-4322	medical	_
26-24	4323-4330	illness	_
26-25	4331-4333	or	_
26-26	4334-4341	central	_
26-27	4342-4349	nervous	_
26-28	4350-4356	system	_
26-29	4357-4365	disorder	_
26-30	4366-4367	(	_
26-31	4368-4371	e.g	_
26-32	4372-4373	.	_

27-1	4374-4382	multiple	_
27-2	4383-4392	sclerosis	_
27-3	4393-4394	,	_
27-4	4395-4403	epilepsy	_
27-5	4404-4405	)	_
27-6	4406-4410	that	_
27-7	4411-4416	would	_
27-8	4417-4423	affect	_
27-9	4424-4429	study	_
27-10	4430-4437	results	_
27-11	4438-4439	;	_
27-12	4440-4448	reported	_
27-13	4449-4458	pregnancy	_
27-14	4459-4461	or	_
27-15	4462-4471	lactation	_
27-16	4472-4473	;	_
27-17	4474-4481	history	_
27-18	4482-4484	of	_
27-19	4485-4496	significant	_
27-20	4497-4501	head	_
27-21	4502-4508	trauma	_
27-22	4509-4510	;	_
27-23	4511-4523	psychotropic	_
27-24	4524-4528	drug	_
27-25	4529-4532	use	_
27-26	4533-4534	(	_
27-27	4535-4542	healthy	_
27-28	4543-4551	subjects	_
27-29	4552-4556	only	_
27-30	4557-4558	)	_
27-31	4559-4560	;	_
27-32	4561-4570	substance	_
27-33	4571-4576	abuse	_
27-34	4577-4583	within	_
27-35	4584-4588	last	_
27-36	4589-4594	three	_
27-37	4595-4601	months	_
27-38	4602-4603	(	_
27-39	4604-4612	patients	_
27-40	4613-4614	)	_
27-41	4615-4617	or	_
27-42	4618-4626	lifetime	_
27-43	4627-4634	history	_
27-44	4635-4637	of	_
27-45	4638-4647	substance	_
27-46	4648-4664	abuse/dependence	_
27-47	4665-4666	(	_
27-48	4667-4674	healthy	_
27-49	4675-4683	subjects	_
27-50	4684-4685	)	_
27-51	4686-4687	;	_
27-52	4688-4691	and	_
27-53	4692-4695	MRI	_
27-54	4696-4713	contra-indicators	_
27-55	4714-4715	(	_
27-56	4716-4719	e.g	_
27-57	4720-4721	.	_

28-1	4722-4727	metal	_
28-2	4728-4736	implants	_
28-3	4737-4738	,	_
28-4	4739-4753	claustrophobia	_
28-5	4754-4755	)	_
28-6	4756-4757	.	_

29-1	4758-4770	Neuroimaging	_
29-2	4771-4775	Data	_
29-3	4776-4787	Acquisition	_
29-4	4788-4789	,	_
29-5	4790-4803	Preprocessing	_
29-6	4804-4805	,	_
29-7	4806-4809	and	_
29-8	4810-4817	Quality	_
29-9	4818-4827	Assurance	_
29-10	4828-4829	A	_
29-11	4830-4839	10-minute	_
29-12	4840-4853	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
29-13	4854-4855	(	_
29-14	4856-4860	eyes	_
29-15	4861-4865	open	_
29-16	4866-4867	,	_
29-17	4868-4876	fixation	_
29-18	4877-4878	)	_
29-19	4879-4883	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
29-20	4884-4890	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
29-21	4891-4898	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
29-22	4899-4909	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
29-23	4910-4914	scan	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
29-24	4915-4918	and	_
29-25	4919-4930	T1-weigthed	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
29-26	4931-4941	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
29-27	4942-4946	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
29-28	4947-4951	were	_
29-29	4952-4961	collected	_
29-30	4962-4964	on	_
29-31	4965-4969	each	_
29-32	4970-4977	subject	_
29-33	4978-4984	during	_
29-34	4985-4986	a	_
29-35	4987-4993	single	_
29-36	4994-5002	scanning	_
29-37	5003-5010	session	_
29-38	5011-5013	on	_
29-39	5014-5015	a	_
29-40	5016-5018	3T	_
29-41	5019-5026	Philips	_
29-42	5027-5033	Intera	_
29-43	5034-5041	Achieva	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
29-44	5042-5045	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
29-45	5046-5053	scanner	_
29-46	5054-5061	located	_
29-47	5062-5064	at	_
29-48	5065-5075	Vanderbilt	_
29-49	5076-5086	University	_
29-50	5087-5096	Institute	_
29-51	5097-5099	of	_
29-52	5100-5107	Imaging	_
29-53	5108-5116	Sciences	_
29-54	5117-5118	(	_
29-55	5119-5124	VUIIS	_
29-56	5125-5126	)	_
29-57	5127-5128	.	_

30-1	5129-5132	The	_
30-2	5133-5146	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-3	5147-5151	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-4	5152-5156	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-5	5157-5160	had	_
30-6	5161-5164	the	_
30-7	5165-5174	following	_
30-8	5175-5185	parameters	_
30-9	5186-5187	:	_
30-10	5188-5190	38	_
30-11	5191-5196	axial	_
30-12	5197-5203	slices	_
30-13	5204-5205	(	_
30-14	5206-5211	slice	_
30-15	5212-5225	thickness=3.0	_
30-16	5226-5228	mm	_
30-17	5229-5230	;	_
30-18	5231-5238	gap=0.3	_
30-19	5239-5241	mm	_
30-20	5242-5243	)	_
30-21	5244-5245	,	_
30-22	5246-5251	field	_
30-23	5252-5254	of	_
30-24	5255-5259	view	_
30-25	5260-5261	(	_
30-26	5262-5265	FOV	_
30-27	5266-5267	)	_
30-28	5268-5274	=80×80	_
30-29	5275-5281	matrix	_
30-30	5282-5283	(	_
30-31	5284-5287	3.0	_
30-32	5288-5294	mm×3.0	_
30-33	5295-5297	mm	_
30-34	5298-5306	in-plane	_
30-35	5307-5317	resolution	_
30-36	5318-5319	)	_
30-37	5320-5321	,	_
30-38	5322-5331	90-degree	_
30-39	5332-5336	flip	_
30-40	5337-5342	angle	_
30-41	5343-5344	,	_
30-42	5345-5348	300	_
30-43	5349-5356	volumes	_
30-44	5357-5358	,	_
30-45	5359-5372	TR/TE=2000/25	_
30-46	5373-5376	ms.	_
30-47	5377-5378	A	_
30-48	5379-5383	high	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
30-49	5384-5394	resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
30-50	5395-5406	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-51	5407-5412	turbo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-52	5413-5418	field	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-53	5419-5423	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-54	5424-5425	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
30-55	5426-5429	TFE	_
30-56	5430-5431	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-57	5432-5442	structural	_
30-58	5443-5447	scan	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
30-59	5448-5449	(	_
30-60	5450-5453	170	_
30-61	5454-5461	sagital	_
30-62	5462-5468	slices	_
30-63	5469-5470	,	_
30-64	5471-5482	FOV=256×256	_
30-65	5483-5489	matrix	_
30-66	5490-5491	,	_
30-67	5492-5495	1.0	_
30-68	5496-5498	mm	_
30-69	5499-5507	isovoxel	_
30-70	5508-5518	resolution	_
30-71	5519-5520	,	_
30-72	5521-5534	TR/TE=8.9/4.6	_
30-73	5535-5537	ms	_
30-74	5538-5539	)	_
30-75	5540-5543	was	_
30-76	5544-5548	also	_
30-77	5549-5557	acquired	_
30-78	5558-5559	.	_

31-1	5560-5571	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
31-2	5572-5582	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
31-3	5583-5589	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
31-4	5590-5594	were	_
31-5	5595-5604	segmented	_
31-6	5605-5609	into	_
31-7	5610-5614	grey	_
31-8	5615-5621	matter	_
31-9	5622-5623	,	_
31-10	5624-5629	white	_
31-11	5630-5636	matter	_
31-12	5637-5638	,	_
31-13	5639-5642	and	_
31-14	5643-5646	CSF	_
31-15	5647-5652	using	_
31-16	5653-5656	the	_
31-17	5657-5668	Voxel-based	_
31-18	5669-5680	Morphometry	_
31-19	5681-5682	,	_
31-20	5683-5690	version	_
31-21	5691-5692	8	_
31-22	5693-5700	toolbox	_
31-23	5701-5702	(	_
31-24	5703-5707	VBM8	_
31-25	5708-5709	;	_
31-26	5710-5714	http	_
31-27	5715-5716	:	_
31-28	5717-5745	//dbm.neuro.uni-jena.de/vbm/	_
31-29	5746-5747	)	_
31-30	5748-5751	for	_
31-31	5752-5763	Statistical	_
31-32	5764-5774	Parametric	_
31-33	5775-5782	Mapping	_
31-34	5783-5790	version	_
31-35	5791-5793	12	_
31-36	5794-5795	(	_
31-37	5796-5801	SPM12	_
31-38	5802-5803	:	_
31-39	5804-5809	https	_
31-40	5810-5811	:	_
31-41	5812-5840	//www.fil.ion.ucl.ac.uk/spm/	_
31-42	5841-5842	)	_
31-43	5843-5844	.	_

32-1	5845-5854	Following	_
32-2	5855-5867	segmentation	_
32-3	5868-5869	,	_
32-4	5870-5874	each	_
32-5	5875-5881	tissue	_
32-6	5882-5887	class	_
32-7	5888-5891	was	_
32-8	5892-5901	spatially	_
32-9	5902-5908	warped	_
32-10	5909-5911	to	_
32-11	5912-5914	an	_
32-12	5915-5924	MNI-space	_
32-13	5925-5933	template	_
32-14	5934-5939	image	_
32-15	5940-5949	comprised	_
32-16	5950-5952	of	_
32-17	5953-5956	550	_
32-18	5957-5965	subjects	_
32-19	5966-5974	included	_
32-20	5975-5979	with	_
32-21	5980-5983	the	_
32-22	5984-5988	VBM8	_
32-23	5989-5996	toolbox	_
32-24	5997-5998	(	_
32-25	5999-6003	http	_
32-26	6004-6005	:	_
32-27	6006-6053	//dbm.neuro.uni-jena.de.libproxy.wustl.edu/vbm/	_
32-28	6054-6055	)	_
32-29	6056-6061	using	_
32-30	6062-6065	the	_
32-31	6066-6070	high	_
32-32	6071-6082	dimensional	_
32-33	6083-6089	DARTEL	_
32-34	6090-6103	normalization	_
32-35	6104-6110	method	_
32-36	6111-6112	.	_

33-1	6113-6123	Functional	_
33-2	6124-6137	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
33-3	6138-6143	scans	_
33-4	6144-6148	were	_
33-5	6149-6159	slice-time	_
33-6	6160-6169	corrected	_
33-7	6170-6171	,	_
33-8	6172-6178	motion	_
33-9	6179-6188	corrected	_
33-10	6189-6190	,	_
33-11	6191-6204	co-registered	_
33-12	6205-6207	to	_
33-13	6208-6214	native	_
33-14	6215-6220	space	_
33-15	6221-6231	structural	_
33-16	6232-6236	data	_
33-17	6237-6238	,	_
33-18	6239-6242	and	_
33-19	6243-6253	normalized	_
33-20	6254-6256	to	_
33-21	6257-6260	MNI	_
33-22	6261-6266	space	_
33-23	6267-6272	using	_
33-24	6273-6279	DARTEL	_
33-25	6280-6291	deformation	_
33-26	6292-6298	fields	_
33-27	6299-6307	obtained	_
33-28	6308-6312	from	_
33-29	6313-6322	spatially	_
33-30	6323-6334	normalizing	_
33-31	6335-6338	the	_
33-32	6339-6350	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-33	6351-6361	anatomical	_
33-34	6362-6368	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-35	6369-6370	.	_

34-1	6371-6374	All	_
34-2	6375-6382	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
34-3	6383-6388	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
34-4	6389-6393	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
34-5	6394-6403	underwent	_
34-6	6404-6411	quality	_
34-7	6412-6421	assurance	_
34-8	6422-6423	(	_
34-9	6424-6426	QA	_
34-10	6427-6428	)	_
34-11	6429-6434	using	_
34-12	6435-6437	an	_
34-13	6438-6447	automated	_
34-14	6448-6450	QA	_
34-15	6451-6459	pipeline	_
34-16	6460-6464	that	_
34-17	6465-6475	calculated	_
34-18	6476-6482	median	_
34-19	6483-6488	voxel	_
34-20	6489-6501	displacement	_
34-21	6502-6503	,	_
34-22	6504-6510	median	_
34-23	6511-6519	temporal	_
34-24	6520-6535	signal-to-noise	_
34-25	6536-6541	ratio	_
34-26	6542-6543	(	_
34-27	6544-6547	SNR	_
34-28	6548-6549	)	_
34-29	6550-6551	,	_
34-30	6552-6555	and	_
34-31	6556-6560	95th	_
34-32	6561-6571	percentile	_
34-33	6572-6578	signal	_
34-34	6579-6585	change	_
34-35	6586-6587	.	_

35-1	6588-6593	Scans	_
35-2	6594-6598	with	_
35-3	6599-6602	log	_
35-4	6603-6606	SNR	_
35-5	6607-6610	and	_
35-6	6611-6614	log	_
35-7	6615-6621	median	_
35-8	6622-6627	voxel	_
35-9	6628-6640	displacement	_
35-10	6641-6646	above	_
35-11	6647-6650	the	_
35-12	6651-6655	95th	_
35-13	6656-6666	percentile	_
35-14	6667-6669	of	_
35-15	6670-6673	the	_
35-16	6674-6686	distribution	_
35-17	6687-6689	of	_
35-18	6690-6693	the	_
35-19	6694-6700	entire	_
35-20	6701-6708	dataset	_
35-21	6709-6713	were	_
35-22	6714-6722	excluded	_
35-23	6723-6727	from	_
35-24	6728-6731	the	_
35-25	6732-6740	analysis	_
35-26	6741-6742	,	_
35-27	6743-6750	leaving	_
35-28	6751-6752	(	_
35-29	6753-6755	as	_
35-30	6756-6766	previously	_
35-31	6767-6776	mentioned	_
35-32	6777-6778	)	_
35-33	6779-6784	n=177	_
35-34	6785-6793	subjects	_
35-35	6794-6801	passing	_
35-36	6802-6807	these	_
35-37	6808-6816	criteria	_
35-38	6817-6818	.	_

36-1	6819-6829	Diagnostic	_
36-2	6830-6836	groups	_
36-3	6837-6840	did	_
36-4	6841-6844	not	_
36-5	6845-6851	differ	_
36-6	6852-6854	on	_
36-7	6855-6861	median	_
36-8	6862-6877	signal-to-noise	_
36-9	6878-6883	ratio	_
36-10	6884-6885	(	_
36-11	6886-6887	F	_
36-12	6888-6889	(	_
36-13	6890-6895	2,174	_
36-14	6896-6897	)	_
36-15	6898-6903	=0.51	_
36-16	6904-6905	,	_
36-17	6906-6911	p=.60	_
36-18	6912-6913	)	_
36-19	6914-6915	,	_
36-20	6916-6922	median	_
36-21	6923-6928	voxel	_
36-22	6929-6941	displacement	_
36-23	6942-6943	(	_
36-24	6944-6945	F	_
36-25	6946-6947	(	_
36-26	6948-6953	2,174	_
36-27	6954-6955	)	_
36-28	6956-6961	=0.33	_
36-29	6962-6963	,	_
36-30	6964-6969	p=.72	_
36-31	6970-6971	)	_
36-32	6972-6973	,	_
36-33	6974-6977	and	_
36-34	6978-6982	95th	_
36-35	6983-6993	percentile	_
36-36	6994-7000	signal	_
36-37	7001-7007	change	_
36-38	7008-7009	(	_
36-39	7010-7011	F	_
36-40	7012-7013	(	_
36-41	7014-7019	2,174	_
36-42	7020-7021	)	_
36-43	7022-7027	=1.24	_
36-44	7028-7029	,	_
36-45	7030-7035	p=.29	_
36-46	7036-7037	)	_
36-47	7038-7039	.	_

37-1	7040-7050	Functional	_
37-2	7051-7063	Connectivity	_
37-3	7064-7072	Analysis	_
37-4	7073-7078	Prior	_
37-5	7079-7087	striatal	_
37-6	7088-7098	functional	_
37-7	7099-7111	connectivity	_
37-8	7112-7119	studies	_
37-9	7120-7122	in	_
37-10	7123-7132	psychosis	_
37-11	7133-7137	used	_
37-12	7138-7144	either	_
37-13	7145-7153	cortical	_
37-14	7154-7159	seeds	_
37-15	7160-7162	to	_
37-16	7163-7170	examine	_
37-17	7171-7183	connectivity	_
37-18	7184-7186	of	_
37-19	7187-7195	cortical	_
37-20	7196-7201	areas	_
37-21	7202-7206	with	_
37-22	7207-7210	the	_
37-23	7211-7219	striatum	_
37-24	7220-7221	(	_
37-25	7222-7225	i.e	_
37-26	7226-7227	.	_

38-1	7228-7234	cortex	_
38-2	7235-7245	seed-based	_
38-3	7246-7254	analysis	_
38-4	7255-7256	)	_
38-5	7257-7258	,	_
38-6	7259-7261	or	_
38-7	7262-7270	striatal	_
38-8	7271-7276	seeds	_
38-9	7277-7279	to	_
38-10	7280-7287	examine	_
38-11	7288-7300	connectivity	_
38-12	7301-7303	of	_
38-13	7304-7312	striatal	_
38-14	7313-7324	sub-regions	_
38-15	7325-7329	with	_
38-16	7330-7333	the	_
38-17	7334-7338	rest	_
38-18	7339-7341	of	_
38-19	7342-7345	the	_
38-20	7346-7351	brain	_
38-21	7352-7353	(	_
38-22	7354-7357	i.e	_
38-23	7358-7359	.	_

39-1	7360-7368	striatum	_
39-2	7369-7379	seed-based	_
39-3	7380-7388	analysis	_
39-4	7389-7390	)	_
39-5	7391-7392	.	_

40-1	7393-7395	We	_
40-2	7396-7400	used	_
40-3	7401-7405	both	_
40-4	7406-7416	approaches	_
40-5	7417-7419	to	_
40-6	7420-7435	comprehensively	_
40-7	7436-7439	map	_
40-8	7440-7450	functional	_
40-9	7451-7463	connectivity	_
40-10	7464-7466	of	_
40-11	7467-7470	the	_
40-12	7471-7479	striatum	_
40-13	7480-7483	and	_
40-14	7484-7494	facilitate	_
40-15	7495-7505	comparison	_
40-16	7506-7508	of	_
40-17	7509-7512	our	_
40-18	7513-7520	results	_
40-19	7521-7523	to	_
40-20	7524-7529	prior	_
40-21	7530-7537	studies	_
40-22	7538-7539	.	_

41-1	7540-7544	Each	_
41-2	7545-7553	approach	_
41-3	7554-7556	is	_
41-4	7557-7566	described	_
41-5	7567-7569	in	_
41-6	7570-7576	detail	_
41-7	7577-7582	below	_
41-8	7583-7584	.	_

42-1	7585-7595	Functional	_
42-2	7596-7608	connectivity	_
42-3	7609-7613	maps	_
42-4	7614-7616	of	_
42-5	7617-7623	cortex	_
42-6	7624-7627	and	_
42-7	7628-7636	striatum	_
42-8	7637-7642	seeds	_
42-9	7643-7647	were	_
42-10	7648-7657	generated	_
42-11	7658-7663	using	_
42-12	7664-7667	the	_
42-13	7668-7677	CONN-fMRI	_
42-14	7678-7685	toolbox	_
42-15	7686-7692	v.17.f	_
42-16	7693-7694	(	_
42-17	7695-7699	http	_
42-18	7700-7701	:	_
42-19	7702-7731	//www.nitrc.org/projects/conn	_
42-20	7732-7733	)	_
42-21	7734-7735	.	_

43-1	7736-7739	The	_
43-2	7740-7744	mean	_
43-3	7745-7749	BOLD	_
43-4	7750-7754	time	_
43-5	7755-7761	series	_
43-6	7762-7765	was	_
43-7	7766-7775	extracted	_
43-8	7776-7780	from	_
43-9	7781-7786	seeds	_
43-10	7787-7790	and	_
43-11	7791-7798	entered	_
43-12	7799-7801	as	_
43-13	7802-7803	a	_
43-14	7804-7813	predictor	_
43-15	7814-7816	in	_
43-16	7817-7818	a	_
43-17	7819-7827	multiple	_
43-18	7828-7838	regression	_
43-19	7839-7846	general	_
43-20	7847-7853	linear	_
43-21	7854-7859	model	_
43-22	7860-7861	(	_
43-23	7862-7865	GLM	_
43-24	7866-7867	)	_
43-25	7868-7869	.	_

44-1	7870-7880	Regressors	_
44-2	7881-7894	corresponding	_
44-3	7895-7897	to	_
44-4	7898-7901	the	_
44-5	7902-7903	6	_
44-6	7904-7910	motion	_
44-7	7911-7921	correction	_
44-8	7922-7932	parameters	_
44-9	7933-7936	and	_
44-10	7937-7942	their	_
44-11	7943-7948	first	_
44-12	7949-7957	temporal	_
44-13	7958-7969	derivatives	_
44-14	7970-7971	,	_
44-15	7972-7977	along	_
44-16	7978-7982	with	_
44-17	7983-7987	grey	_
44-18	7988-7994	matter	_
44-19	7995-7996	,	_
44-20	7997-8002	white	_
44-21	8003-8009	matter	_
44-22	8010-8011	,	_
44-23	8012-8015	and	_
44-24	8016-8019	CSF	_
44-25	8020-8024	were	_
44-26	8025-8033	included	_
44-27	8034-8036	to	_
44-28	8037-8043	remove	_
44-29	8044-8052	variance	_
44-30	8053-8060	related	_
44-31	8061-8063	to	_
44-32	8064-8068	head	_
44-33	8069-8075	motion	_
44-34	8076-8077	,	_
44-35	8078-8081	the	_
44-36	8082-8088	global	_
44-37	8089-8093	grey	_
44-38	8094-8100	matter	_
44-39	8101-8107	signal	_
44-40	8108-8109	,	_
44-41	8110-8115	white	_
44-42	8116-8122	matter	_
44-43	8123-8124	,	_
44-44	8125-8128	and	_
44-45	8129-8132	CSF	_
44-46	8133-8134	,	_
44-47	8135-8147	respectively	_
44-48	8148-8149	.	_

45-1	8150-8152	In	_
45-2	8153-8161	addition	_
45-3	8162-8164	to	_
45-4	8165-8167	12	_
45-5	8168-8176	nuisance	_
45-6	8177-8187	regressors	_
45-7	8188-8195	related	_
45-8	8196-8198	to	_
45-9	8199-8205	motion	_
45-10	8206-8207	(	_
45-11	8208-8209	6	_
45-12	8210-8232	translations/rotations	_
45-13	8233-8236	and	_
45-14	8237-8242	their	_
45-15	8243-8251	temporal	_
45-16	8252-8257	first	_
45-17	8258-8269	derivatives	_
45-18	8270-8271	)	_
45-19	8272-8273	,	_
45-20	8274-8277	the	_
45-21	8278-8283	first	_
45-22	8284-8285	6	_
45-23	8286-8295	principal	_
45-24	8296-8306	components	_
45-25	8307-8311	were	_
45-26	8312-8321	extracted	_
45-27	8322-8326	from	_
45-28	8327-8331	each	_
45-29	8332-8339	subject	_
45-30	8340-8341	’	_
45-31	8342-8343	s	_
45-32	8344-8349	white	_
45-33	8350-8356	matter	_
45-34	8357-8360	and	_
45-35	8361-8364	CSF	_
45-36	8365-8378	segmentations	_
45-37	8379-8380	(	_
45-38	8381-8384	i.e	_
45-39	8385-8386	.	_

46-1	8387-8397	anatomical	_
46-2	8398-8405	CompCor	_
46-3	8406-8407	)	_
46-4	8408-8409	.	_

47-1	8410-8420	Anatomical	_
47-2	8421-8428	CompCor	_
47-3	8429-8432	has	_
47-4	8433-8437	been	_
47-5	8438-8443	shown	_
47-6	8444-8446	to	_
47-7	8447-8449	be	_
47-8	8450-8452	at	_
47-9	8453-8458	least	_
47-10	8459-8461	as	_
47-11	8462-8471	effective	_
47-12	8472-8474	as	_
47-13	8475-8482	another	_
47-14	8483-8491	commonly	_
47-15	8492-8496	used	_
47-16	8497-8505	approach	_
47-17	8506-8507	,	_
47-18	8508-8511	the	_
47-19	8512-8513	“	_
47-20	8514-8523	scrubbing	_
47-21	8524-8525	”	_
47-22	8526-8535	procedure	_
47-23	8536-8545	described	_
47-24	8546-8548	by	_
47-25	8549-8554	Power	_
47-26	8555-8557	et	_
47-27	8558-8561	al.	_
47-28	8562-8563	,	_
47-29	8564-8566	at	_
47-30	8567-8577	mitigating	_
47-31	8578-8581	the	_
47-32	8582-8590	residual	_
47-33	8591-8598	effects	_
47-34	8599-8601	of	_
47-35	8602-8606	head	_
47-36	8607-8613	motion	_
47-37	8614-8616	on	_
47-38	8617-8627	functional	_
47-39	8628-8640	connectivity	_
47-40	8641-8642	.	_

48-1	8643-8649	Motion	_
48-2	8650-8660	correction	_
48-3	8661-8671	parameters	_
48-4	8672-8676	were	_
48-5	8677-8686	regressed	_
48-6	8687-8690	out	_
48-7	8691-8696	prior	_
48-8	8697-8699	to	_
48-9	8700-8708	temporal	_
48-10	8709-8718	band-pass	_
48-11	8719-8728	filtering	_
48-12	8729-8730	.	_

49-1	8731-8741	Performing	_
49-2	8742-8747	these	_
49-3	8748-8753	steps	_
49-4	8754-8756	in	_
49-5	8757-8764	reverse	_
49-6	8765-8770	order	_
49-7	8771-8772	(	_
49-8	8773-8776	i.e	_
49-9	8777-8778	.	_

50-1	8779-8788	band-pass	_
50-2	8789-8798	filtering	_
50-3	8799-8805	before	_
50-4	8806-8814	nuisance	_
50-5	8815-8825	regression	_
50-6	8826-8827	)	_
50-7	8828-8841	re-introduces	_
50-8	8842-8850	nuisance	_
50-9	8851-8858	related	_
50-10	8859-8868	variation	_
50-11	8869-8876	thereby	_
50-12	8877-8891	overestimating	_
50-13	8892-8904	connectivity	_
50-14	8905-8914	estimates	_
50-15	8915-8918	and	_
50-16	8919-8931	exacerbating	_
50-17	8932-8935	the	_
50-18	8936-8943	effects	_
50-19	8944-8946	of	_
50-20	8947-8951	head	_
50-21	8952-8958	motion	_
50-22	8959-8960	.	_

51-1	8961-8963	In	_
51-2	8964-8972	addition	_
51-3	8973-8974	,	_
51-4	8975-8976	a	_
51-5	8977-8981	mask	_
51-6	8982-8985	was	_
51-7	8986-8993	created	_
51-8	8994-8997	for	_
51-9	8998-9002	each	_
51-10	9003-9010	subject	_
51-11	9011-9012	’	_
51-12	9013-9014	s	_
51-13	9015-9019	mean	_
51-14	9020-9024	fMRI	_
51-15	9025-9030	image	_
51-16	9031-9033	to	_
51-17	9034-9042	identify	_
51-18	9043-9051	in-brain	_
51-19	9052-9058	voxels	_
51-20	9059-9060	(	_
51-21	9061-9065	i.e.	_
51-22	9066-9067	,	_
51-23	9068-9070	an	_
51-24	9071-9079	in-brain	_
51-25	9080-9084	mask	_
51-26	9085-9086	)	_
51-27	9087-9090	and	_
51-28	9091-9098	exclude	_
51-29	9099-9105	voxels	_
51-30	9106-9110	with	_
51-31	9111-9114	low	_
51-32	9115-9118	SNR	_
51-33	9119-9120	.	_

52-1	9121-9128	Briefly	_
52-2	9129-9130	,	_
52-3	9131-9136	after	_
52-4	9137-9146	rescaling	_
52-5	9147-9150	and	_
52-6	9151-9164	standardizing	_
52-7	9165-9169	each	_
52-8	9170-9177	subject	_
52-9	9178-9179	’	_
52-10	9180-9181	s	_
52-11	9182-9187	voxel	_
52-12	9188-9197	intensity	_
52-13	9198-9199	,	_
52-14	9200-9203	the	_
52-15	9204-9208	mean	_
52-16	9209-9214	voxel	_
52-17	9215-9224	intensity	_
52-18	9225-9228	for	_
52-19	9229-9232	all	_
52-20	9233-9236	177	_
52-21	9237-9245	subjects	_
52-22	9246-9249	was	_
52-23	9250-9260	calculated	_
52-24	9261-9262	,	_
52-25	9263-9266	and	_
52-26	9267-9268	a	_
52-27	9269-9278	threshold	_
52-28	9279-9282	was	_
52-29	9283-9293	identified	_
52-30	9294-9299	using	_
52-31	9300-9303	the	_
52-32	9304-9309	SPM12	_
52-33	9310-9311	’	_
52-34	9312-9313	s	_
52-35	9314-9322	antimode	_
52-36	9323-9331	function	_
52-37	9332-9334	to	_
52-38	9335-9343	estimate	_
52-39	9344-9345	a	_
52-40	9346-9360	brain-nonbrain	_
52-41	9361-9370	threshold	_
52-42	9371-9372	.	_

53-1	9373-9376	Any	_
53-2	9377-9383	voxels	_
53-3	9384-9388	that	_
53-4	9389-9392	did	_
53-5	9393-9396	not	_
53-6	9397-9401	meet	_
53-7	9402-9406	this	_
53-8	9407-9415	in-brain	_
53-9	9416-9425	threshold	_
53-10	9426-9430	were	_
53-11	9431-9438	removed	_
53-12	9439-9440	,	_
53-13	9441-9446	after	_
53-14	9447-9455	applying	_
53-15	9456-9459	the	_
53-16	9460-9464	mask	_
53-17	9465-9467	to	_
53-18	9468-9471	MNI	_
53-19	9472-9477	space	_
53-20	9478-9479	.	_

54-1	9480-9484	This	_
54-2	9485-9489	mask	_
54-3	9490-9493	was	_
54-4	9494-9498	used	_
54-5	9499-9501	in	_
54-6	9502-9505	all	_
54-7	9506-9514	cortical	_
54-8	9515-9523	analyses	_
54-9	9524-9526	in	_
54-10	9527-9529	to	_
54-11	9530-9536	remove	_
54-12	9537-9546	non-brain	_
54-13	9547-9550	and	_
54-14	9551-9554	low	_
54-15	9555-9558	SNR	_
54-16	9559-9565	voxels	_
54-17	9566-9570	from	_
54-18	9571-9574	the	_
54-19	9575-9583	analyses	_
54-20	9584-9585	.	_

55-1	9586-9592	Cortex	_
55-2	9593-9603	Seed-based	_
55-3	9604-9612	Analysis	_
55-4	9613-9616	The	_
55-5	9617-9626	7-network	_
55-6	9627-9635	cortical	_
55-7	9636-9648	parcellation	_
55-8	9649-9659	identified	_
55-9	9660-9662	by	_
55-10	9663-9666	Yeo	_
55-11	9667-9669	et	_
55-12	9670-9672	al	_
55-13	9673-9674	.	_

56-1	9675-9678	was	_
56-2	9679-9683	used	_
56-3	9684-9686	to	_
56-4	9687-9693	define	_
56-5	9694-9699	seeds	_
56-6	9700-9703	for	_
56-7	9704-9707	the	_
56-8	9708-9716	cortical	_
56-9	9717-9727	seed-based	_
56-10	9728-9736	analysis	_
56-11	9737-9738	(	_
56-12	9739-9742	see	_
56-13	9743-9749	Figure	_
56-14	9750-9752	1a	_
56-15	9753-9754	)	_
56-16	9755-9756	.	_

57-1	9757-9764	Briefly	_
57-2	9765-9766	,	_
57-3	9767-9770	the	_
57-4	9771-9774	Yeo	_
57-5	9775-9784	7-network	_
57-6	9785-9793	cortical	_
57-7	9794-9806	parcellation	_
57-8	9807-9809	is	_
57-9	9810-9819	comprised	_
57-10	9820-9822	of	_
57-11	9823-9826	the	_
57-12	9827-9834	default	_
57-13	9835-9839	mode	_
57-14	9840-9841	(	_
57-15	9842-9845	DMN	_
57-16	9846-9847	)	_
57-17	9848-9849	,	_
57-18	9850-9865	fronto-parietal	_
57-19	9866-9867	(	_
57-20	9868-9871	FPN	_
57-21	9872-9873	)	_
57-22	9874-9875	,	_
57-23	9876-9884	salience	_
57-24	9885-9886	(	_
57-25	9887-9890	SAL	_
57-26	9891-9892	)	_
57-27	9893-9894	,	_
57-28	9895-9901	limbic	_
57-29	9902-9903	(	_
57-30	9904-9906	LN	_
57-31	9907-9908	)	_
57-32	9909-9910	,	_
57-33	9911-9923	sensorimotor	_
57-34	9924-9925	(	_
57-35	9926-9929	SMN	_
57-36	9930-9931	)	_
57-37	9932-9933	,	_
57-38	9934-9940	dorsal	_
57-39	9941-9950	attention	_
57-40	9951-9952	(	_
57-41	9953-9956	DAN	_
57-42	9957-9958	)	_
57-43	9959-9960	,	_
57-44	9961-9964	and	_
57-45	9965-9971	visual	_
57-46	9972-9973	(	_
57-47	9974-9976	VN	_
57-48	9977-9978	)	_
57-49	9979-9987	networks	_
57-50	9988-9989	.	_

58-1	9990-10000	Functional	_
58-2	10001-10013	connectivity	_
58-3	10014-10018	maps	_
58-4	10019-10023	were	_
58-5	10024-10033	generated	_
58-6	10034-10037	for	_
58-7	10038-10042	each	_
58-8	10043-10045	of	_
58-9	10046-10049	the	_
58-10	10050-10053	Yeo	_
58-11	10054-10062	networks	_
58-12	10063-10064	,	_
58-13	10065-10071	except	_
58-14	10072-10075	the	_
58-15	10076-10079	DAN	_
58-16	10080-10083	and	_
58-17	10084-10086	VN	_
58-18	10087-10092	which	_
58-19	10093-10097	have	_
58-20	10098-10105	minimal	_
58-21	10106-10116	functional	_
58-22	10117-10129	connectivity	_
58-23	10130-10134	with	_
58-24	10135-10138	the	_
58-25	10139-10147	striatum	_
58-26	10148-10149	.	_

59-1	10150-10153	The	_
59-2	10154-10164	functional	_
59-3	10165-10177	connectivity	_
59-4	10178-10182	maps	_
59-5	10183-10187	were	_
59-6	10188-10194	masked	_
59-7	10195-10197	to	_
59-8	10198-10202	only	_
59-9	10203-10210	include	_
59-10	10211-10217	voxels	_
59-11	10218-10220	in	_
59-12	10221-10224	the	_
59-13	10225-10233	striatum	_
59-14	10234-10235	.	_

60-1	10236-10238	To	_
60-2	10239-10247	maximize	_
60-3	10248-10259	statistical	_
60-4	10260-10265	power	_
60-5	10266-10267	,	_
60-6	10268-10270	we	_
60-7	10271-10276	first	_
60-8	10277-10286	performed	_
60-9	10287-10288	a	_
60-10	10289-10307	region-of-interest	_
60-11	10308-10309	(	_
60-12	10310-10313	ROI	_
60-13	10314-10315	)	_
60-14	10316-10324	analysis	_
60-15	10325-10329	that	_
60-16	10330-10339	generated	_
60-17	10340-10341	a	_
60-18	10342-10348	single	_
60-19	10349-10354	value	_
60-20	10355-10368	approximating	_
60-21	10369-10376	overall	_
60-22	10377-10387	functional	_
60-23	10388-10400	connectivity	_
60-24	10401-10403	of	_
60-25	10404-10408	each	_
60-26	10409-10417	cortical	_
60-27	10418-10422	seed	_
60-28	10423-10427	with	_
60-29	10428-10431	the	_
60-30	10432-10440	striatum	_
60-31	10441-10442	.	_

61-1	10443-10455	Specifically	_
61-2	10456-10457	,	_
61-3	10458-10461	the	_
61-4	10462-10472	unsmoothed	_
61-5	10473-10481	cortical	_
61-6	10482-10492	seed-based	_
61-7	10493-10505	connectivity	_
61-8	10506-10510	maps	_
61-9	10511-10515	were	_
61-10	10516-10523	entered	_
61-11	10524-10528	into	_
61-12	10529-10537	separate	_
61-13	10538-10548	one-sample	_
61-14	10549-10559	voxel-wise	_
61-15	10560-10567	t-tests	_
61-16	10568-10570	to	_
61-17	10571-10579	identify	_
61-18	10580-10586	voxels	_
61-19	10587-10589	in	_
61-20	10590-10593	the	_
61-21	10594-10602	striatum	_
61-22	10603-10613	exhibiting	_
61-23	10614-10622	positive	_
61-24	10623-10633	functional	_
61-25	10634-10646	connectivity	_
61-26	10647-10651	with	_
61-27	10652-10656	each	_
61-28	10657-10665	cortical	_
61-29	10666-10670	seed	_
61-30	10671-10672	.	_

62-1	10673-10677	This	_
62-2	10678-10686	analysis	_
62-3	10687-10695	included	_
62-4	10696-10699	the	_
62-5	10700-10706	entire	_
62-6	10707-10713	cohort	_
62-7	10714-10716	of	_
62-8	10717-10722	study	_
62-9	10723-10735	participants	_
62-10	10736-10737	,	_
62-11	10738-10747	including	_
62-12	10748-10755	healthy	_
62-13	10756-10764	subjects	_
62-14	10765-10768	and	_
62-15	10769-10780	individuals	_
62-16	10781-10785	with	_
62-17	10786-10787	a	_
62-18	10788-10797	psychotic	_
62-19	10798-10806	disorder	_
62-20	10807-10808	.	_

63-1	10809-10812	The	_
63-2	10813-10822	resultant	_
63-3	10823-10834	statistical	_
63-4	10835-10845	parametric	_
63-5	10846-10850	maps	_
63-6	10851-10852	(	_
63-7	10853-10856	SPM	_
63-8	10857-10858	)	_
63-9	10859-10863	were	_
63-10	10864-10875	thresholded	_
63-11	10876-10878	at	_
63-12	10879-10889	voxel-wise	_
63-13	10890-10901	family-wise	_
63-14	10902-10907	error	_
63-15	10908-10909	(	_
63-16	10910-10913	FWE	_
63-17	10914-10915	)	_
63-18	10916-10925	corrected	_
63-19	10926-10931	p=.05	_
63-20	10932-10933	,	_
63-21	10934-10941	minimum	_
63-22	10942-10949	cluster	_
63-23	10950-10957	size=10	_
63-24	10958-10964	voxels	_
63-25	10965-10966	,	_
63-26	10967-10970	and	_
63-27	10971-10974	the	_
63-28	10975-10976	‘	_
63-29	10977-10989	eigenvariate	_
63-30	10990-10991	’	_
63-31	10992-11000	function	_
63-32	11001-11003	in	_
63-33	11004-11009	SPM12	_
63-34	11010-11013	was	_
63-35	11014-11018	used	_
63-36	11019-11021	to	_
63-37	11022-11029	extract	_
63-38	11030-11033	the	_
63-39	11034-11039	first	_
63-40	11040-11049	principal	_
63-41	11050-11059	component	_
63-42	11060-11064	from	_
63-43	11065-11068	the	_
63-44	11069-11075	voxels	_
63-45	11076-11080	that	_
63-46	11081-11089	survived	_
63-47	11090-11102	thresholding	_
63-48	11103-11104	.	_

64-1	11105-11109	This	_
64-2	11110-11117	yielded	_
64-3	11118-11119	a	_
64-4	11120-11126	single	_
64-5	11127-11134	measure	_
64-6	11135-11137	of	_
64-7	11138-11148	functional	_
64-8	11149-11161	connectivity	_
64-9	11162-11166	with	_
64-10	11167-11170	the	_
64-11	11171-11179	striatum	_
64-12	11180-11183	for	_
64-13	11184-11188	each	_
64-14	11189-11197	cortical	_
64-15	11198-11202	seed	_
64-16	11203-11206	for	_
64-17	11207-11211	each	_
64-18	11212-11219	subject	_
64-19	11220-11221	.	_

65-1	11222-11227	These	_
65-2	11228-11236	measures	_
65-3	11237-11243	served	_
65-4	11244-11246	as	_
65-5	11247-11256	dependent	_
65-6	11257-11266	variables	_
65-7	11267-11269	in	_
65-8	11270-11271	a	_
65-9	11272-11280	repeated	_
65-10	11281-11289	measures	_
65-11	11290-11296	ANCOVA	_
65-12	11297-11301	with	_
65-13	11302-11309	network	_
65-14	11310-11317	entered	_
65-15	11318-11320	as	_
65-16	11321-11322	a	_
65-17	11323-11332	repeating	_
65-18	11333-11341	variable	_
65-19	11342-11345	and	_
65-20	11346-11356	diagnostic	_
65-21	11357-11362	group	_
65-22	11363-11364	(	_
65-23	11365-11372	healthy	_
65-24	11373-11381	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
65-25	11382-11383	,	_
65-26	11384-11397	schizophrenia	_
65-27	11398-11399	,	_
65-28	11400-11409	psychotic	_
65-29	11410-11417	bipolar	_
65-30	11418-11426	disorder	_
65-31	11427-11428	)	_
65-32	11429-11436	entered	_
65-33	11437-11439	as	_
65-34	11440-11441	a	_
65-35	11442-11458	between-subjects	_
65-36	11459-11465	factor	_
65-37	11466-11471	along	_
65-38	11472-11476	with	_
65-39	11477-11480	age	_
65-40	11481-11484	and	_
65-41	11485-11488	sex	_
65-42	11489-11491	as	_
65-43	11492-11502	covariates	_
65-44	11503-11504	.	_

66-1	11505-11516	Significant	_
66-2	11517-11521	main	_
66-3	11522-11529	effects	_
66-4	11530-11533	and	_
66-5	11534-11546	interactions	_
66-6	11547-11551	were	_
66-7	11552-11563	followed-up	_
66-8	11564-11568	with	_
66-9	11569-11577	post-hoc	_
66-10	11578-11585	t-tests	_
66-11	11586-11587	.	_

67-1	11588-11591	The	_
67-2	11592-11604	well-powered	_
67-3	11605-11608	ROI	_
67-4	11609-11617	approach	_
67-5	11618-11627	described	_
67-6	11628-11633	above	_
67-7	11634-11637	was	_
67-8	11638-11649	followed-up	_
67-9	11650-11654	with	_
67-10	11655-11665	voxel-wise	_
67-11	11666-11674	analyses	_
67-12	11675-11684	comparing	_
67-13	11685-11695	functional	_
67-14	11696-11708	connectivity	_
67-15	11709-11711	of	_
67-16	11712-11716	each	_
67-17	11717-11725	cortical	_
67-18	11726-11730	seed	_
67-19	11731-11737	within	_
67-20	11738-11741	the	_
67-21	11742-11750	striatum	_
67-22	11751-11758	between	_
67-23	11759-11765	groups	_
67-24	11766-11767	,	_
67-25	11768-11770	in	_
67-26	11771-11776	order	_
67-27	11777-11779	to	_
67-28	11780-11787	examine	_
67-29	11788-11791	the	_
67-30	11792-11800	specific	_
67-31	11801-11810	locations	_
67-32	11811-11813	of	_
67-33	11814-11826	connectivity	_
67-34	11827-11838	differences	_
67-35	11839-11846	between	_
67-36	11847-11850	the	_
67-37	11851-11857	groups	_
67-38	11858-11859	.	_

68-1	11860-11867	Briefly	_
68-2	11868-11869	,	_
68-3	11870-11873	the	_
68-4	11874-11884	unsmoothed	_
68-5	11885-11893	cortical	_
68-6	11894-11904	seed-based	_
68-7	11905-11917	connectivity	_
68-8	11918-11922	maps	_
68-9	11923-11927	were	_
68-10	11928-11936	analyzed	_
68-11	11937-11947	separately	_
68-12	11948-11953	using	_
68-13	11954-11961	one-way	_
68-14	11962-11968	ANOVAs	_
68-15	11969-11973	with	_
68-16	11974-11979	group	_
68-17	11980-11981	(	_
68-18	11982-11989	healthy	_
68-19	11990-11998	controls	_
68-20	11999-12000	,	_
68-21	12001-12014	schizophrenia	_
68-22	12015-12016	,	_
68-23	12017-12026	psychotic	_
68-24	12027-12034	bipolar	_
68-25	12035-12043	disorder	_
68-26	12044-12045	)	_
68-27	12046-12053	entered	_
68-28	12054-12056	as	_
68-29	12057-12058	a	_
68-30	12059-12075	between-subjects	_
68-31	12076-12084	variable	_
68-32	12085-12090	along	_
68-33	12091-12095	with	_
68-34	12096-12099	age	_
68-35	12100-12103	and	_
68-36	12104-12107	sex	_
68-37	12108-12110	as	_
68-38	12111-12121	covariates	_
68-39	12122-12123	.	_

69-1	12124-12134	Voxel-wise	_
69-2	12135-12141	ANOVAs	_
69-3	12142-12146	were	_
69-4	12147-12153	masked	_
69-5	12154-12158	with	_
69-6	12159-12162	the	_
69-7	12163-12173	one-sample	_
69-8	12174-12180	t-test	_
69-9	12181-12188	results	_
69-10	12189-12198	described	_
69-11	12199-12204	above	_
69-12	12205-12209	such	_
69-13	12210-12214	that	_
69-14	12215-12219	only	_
69-15	12220-12226	voxels	_
69-16	12227-12231	that	_
69-17	12232-12244	demonstrated	_
69-18	12245-12253	positive	_
69-19	12254-12264	functional	_
69-20	12265-12277	connectivity	_
69-21	12278-12282	with	_
69-22	12283-12286	the	_
69-23	12287-12299	cortex-based	_
69-24	12300-12305	seeds	_
69-25	12306-12310	were	_
69-26	12311-12319	included	_
69-27	12320-12322	in	_
69-28	12323-12326	the	_
69-29	12327-12335	analysis	_
69-30	12336-12337	.	_

70-1	12338-12345	Results	_
70-2	12346-12350	were	_
70-3	12351-12362	thresholded	_
70-4	12363-12365	at	_
70-5	12366-12379	cluster-level	_
70-6	12380-12388	pFWE=.05	_
70-7	12389-12392	for	_
70-8	12393-12403	voxel-wise	_
70-9	12404-12410	p=.001	_
70-10	12411-12412	.	_

71-1	12413-12421	Striatum	_
71-2	12422-12432	Seed-based	_
71-3	12433-12441	Analysis	_
71-4	12442-12444	We	_
71-5	12445-12449	used	_
71-6	12450-12453	the	_
71-7	12454-12462	striatum	_
71-8	12463-12468	seeds	_
71-9	12469-12473	from	_
71-10	12474-12482	previous	_
71-11	12483-12491	striatal	_
71-12	12492-12502	seed-based	_
71-13	12503-12515	connectivity	_
71-14	12516-12524	research	_
71-15	12525-12526	.	_

72-1	12527-12532	These	_
72-2	12533-12541	striatum	_
72-3	12542-12547	seeds	_
72-4	12548-12551	are	_
72-5	12552-12561	comprised	_
72-6	12562-12564	of	_
72-7	12565-12568	six	_
72-8	12569-12582	3.5-mm-radius	_
72-9	12583-12592	spherical	_
72-10	12593-12597	ROIs	_
72-11	12598-12599	,	_
72-12	12600-12608	totaling	_
72-13	12609-12614	three	_
72-14	12615-12624	bilateral	_
72-15	12625-12632	caudate	_
72-16	12633-12636	and	_
72-17	12637-12642	three	_
72-18	12643-12652	bilateral	_
72-19	12653-12660	putamen	_
72-20	12661-12668	regions	_
72-21	12669-12682	corresponding	_
72-22	12683-12685	to	_
72-23	12686-12687	:	_
72-24	12688-12694	dorsal	_
72-25	12695-12702	caudate	_
72-26	12703-12704	(	_
72-27	12705-12707	DC	_
72-28	12708-12709	;	_
72-29	12710-12715	x=±13	_
72-30	12716-12717	,	_
72-31	12718-12722	y=15	_
72-32	12723-12724	,	_
72-33	12725-12728	z=9	_
72-34	12729-12730	)	_
72-35	12731-12732	,	_
72-36	12733-12741	superior	_
72-37	12742-12749	ventral	_
72-38	12750-12757	caudate	_
72-39	12758-12759	(	_
72-40	12760-12763	sVC	_
72-41	12764-12765	;	_
72-42	12766-12771	x=±10	_
72-43	12772-12773	,	_
72-44	12774-12778	y=15	_
72-45	12779-12780	,	_
72-46	12781-12784	z=0	_
72-47	12785-12786	)	_
72-48	12787-12788	,	_
72-49	12789-12797	inferior	_
72-50	12798-12805	ventral	_
72-51	12806-12813	caudate	_
72-52	12814-12815	(	_
72-53	12816-12819	iVC	_
72-54	12820-12821	;	_
72-55	12822-12826	x=±9	_
72-56	12827-12828	,	_
72-57	12829-12832	y=9	_
72-58	12833-12834	,	_
72-59	12835-12839	z=−8	_
72-60	12840-12841	)	_
72-61	12842-12843	,	_
72-62	12844-12855	dorsocaudal	_
72-63	12856-12863	putamen	_
72-64	12864-12865	(	_
72-65	12866-12870	dcPT	_
72-66	12871-12872	;	_
72-67	12873-12878	x=±28	_
72-68	12879-12880	,	_
72-69	12881-12884	y=1	_
72-70	12885-12886	,	_
72-71	12887-12890	z=3	_
72-72	12891-12892	)	_
72-73	12893-12894	,	_
72-74	12895-12907	dorsorostral	_
72-75	12908-12915	putamen	_
72-76	12916-12917	(	_
72-77	12918-12922	drPT	_
72-78	12923-12924	;	_
72-79	12925-12930	x=±25	_
72-80	12931-12932	,	_
72-81	12933-12936	y=8	_
72-82	12937-12938	,	_
72-83	12939-12942	z=6	_
72-84	12943-12944	)	_
72-85	12945-12946	,	_
72-86	12947-12950	and	_
72-87	12951-12954	the	_
72-88	12955-12968	ventrorostral	_
72-89	12969-12976	putamen	_
72-90	12977-12978	(	_
72-91	12979-12983	vrPT	_
72-92	12984-12985	;	_
72-93	12986-12991	x=±20	_
72-94	12992-12993	,	_
72-95	12994-12998	y=12	_
72-96	12999-13000	,	_
72-97	13001-13005	z=−3	_
72-98	13006-13007	)	_
72-99	13008-13009	.	_

73-1	13010-13020	Functional	_
73-2	13021-13033	connectivity	_
73-3	13034-13038	maps	_
73-4	13039-13043	were	_
73-5	13044-13053	generated	_
73-6	13054-13057	for	_
73-7	13058-13062	each	_
73-8	13063-13065	of	_
73-9	13066-13071	these	_
73-10	13072-13080	striatum	_
73-11	13081-13086	seeds	_
73-12	13087-13088	.	_

74-1	13089-13099	Functional	_
74-2	13100-13112	connectivity	_
74-3	13113-13117	maps	_
74-4	13118-13122	were	_
74-5	13123-13129	masked	_
74-6	13130-13132	to	_
74-7	13133-13137	only	_
74-8	13138-13145	include	_
74-9	13146-13152	voxels	_
74-10	13153-13155	in	_
74-11	13156-13159	the	_
74-12	13160-13166	cortex	_
74-13	13167-13168	(	_
74-14	13169-13174	using	_
74-15	13175-13178	the	_
74-16	13179-13187	in-brain	_
74-17	13188-13192	mask	_
74-18	13193-13201	detailed	_
74-19	13202-13204	in	_
74-20	13205-13208	the	_
74-21	13209-13219	Supplement	_
74-22	13220-13221	)	_
74-23	13222-13225	and	_
74-24	13226-13234	smoothed	_
74-25	13235-13236	(	_
74-26	13237-13238	6	_
74-27	13239-13241	mm	_
74-28	13242-13243	)	_
74-29	13244-13245	.	_

75-1	13246-13247	A	_
75-2	13248-13258	one-sample	_
75-3	13259-13269	voxel-wise	_
75-4	13270-13276	t-test	_
75-5	13277-13280	was	_
75-6	13281-13290	performed	_
75-7	13291-13294	for	_
75-8	13295-13299	each	_
75-9	13300-13308	striatum	_
75-10	13309-13313	seed	_
75-11	13314-13316	to	_
75-12	13317-13325	identify	_
75-13	13326-13332	voxels	_
75-14	13333-13335	in	_
75-15	13336-13339	the	_
75-16	13340-13346	cortex	_
75-17	13347-13357	exhibiting	_
75-18	13358-13366	positive	_
75-19	13367-13377	functional	_
75-20	13378-13390	connectivity	_
75-21	13391-13395	with	_
75-22	13396-13400	each	_
75-23	13401-13409	striatum	_
75-24	13410-13414	seed	_
75-25	13415-13416	.	_

76-1	13417-13420	The	_
76-2	13421-13430	resultant	_
76-3	13431-13442	statistical	_
76-4	13443-13453	parametric	_
76-5	13454-13458	maps	_
76-6	13459-13460	(	_
76-7	13461-13464	SPM	_
76-8	13465-13466	)	_
76-9	13467-13471	were	_
76-10	13472-13483	thresholded	_
76-11	13484-13486	at	_
76-12	13487-13497	voxel-wise	_
76-13	13498-13504	p=.001	_
76-14	13505-13506	.	_

77-1	13507-13512	Group	_
77-2	13513-13524	differences	_
77-3	13525-13527	in	_
77-4	13528-13538	functional	_
77-5	13539-13551	connectivity	_
77-6	13552-13554	of	_
77-7	13555-13559	each	_
77-8	13560-13568	striatum	_
77-9	13569-13573	seed	_
77-10	13574-13578	were	_
77-11	13579-13583	then	_
77-12	13584-13592	analyzed	_
77-13	13593-13598	using	_
77-14	13599-13600	a	_
77-15	13601-13608	one-way	_
77-16	13609-13614	ANOVA	_
77-17	13615-13619	with	_
77-18	13620-13625	group	_
77-19	13626-13627	(	_
77-20	13628-13635	healthy	_
77-21	13636-13644	controls	_
77-22	13645-13646	,	_
77-23	13647-13660	schizophrenia	_
77-24	13661-13662	,	_
77-25	13663-13672	psychotic	_
77-26	13673-13680	bipolar	_
77-27	13681-13689	disorder	_
77-28	13690-13691	)	_
77-29	13692-13699	entered	_
77-30	13700-13702	as	_
77-31	13703-13704	a	_
77-32	13705-13721	between-subjects	_
77-33	13722-13730	variable	_
77-34	13731-13736	along	_
77-35	13737-13741	with	_
77-36	13742-13745	age	_
77-37	13746-13749	and	_
77-38	13750-13753	sex	_
77-39	13754-13756	as	_
77-40	13757-13767	covariates	_
77-41	13768-13769	.	_

78-1	13770-13775	These	_
78-2	13776-13784	analyses	_
78-3	13785-13789	were	_
78-4	13790-13796	masked	_
78-5	13797-13801	with	_
78-6	13802-13805	the	_
78-7	13806-13816	one-sample	_
78-8	13817-13823	t-test	_
78-9	13824-13831	results	_
78-10	13832-13841	described	_
78-11	13842-13847	above	_
78-12	13848-13852	such	_
78-13	13853-13857	that	_
78-14	13858-13862	only	_
78-15	13863-13869	voxels	_
78-16	13870-13874	that	_
78-17	13875-13887	demonstrated	_
78-18	13888-13896	positive	_
78-19	13897-13907	functional	_
78-20	13908-13920	connectivity	_
78-21	13921-13925	with	_
78-22	13926-13940	striatum-based	_
78-23	13941-13946	seeds	_
78-24	13947-13951	were	_
78-25	13952-13960	included	_
78-26	13961-13963	in	_
78-27	13964-13967	the	_
78-28	13968-13976	analysis	_
78-29	13977-13978	.	_

79-1	13979-13986	Results	_
79-2	13987-13991	were	_
79-3	13992-14003	thresholded	_
79-4	14004-14006	at	_
79-5	14007-14020	cluster-level	_
79-6	14021-14029	pFWE=.05	_
79-7	14030-14033	for	_
79-8	14034-14044	voxel-wise	_
79-9	14045-14051	p=.001	_
79-10	14052-14053	.	_

80-1	14054-14061	Testing	_
80-2	14062-14074	Associations	_
80-3	14075-14082	Between	_
80-4	14083-14091	Striatal	_
80-5	14092-14104	Connectivity	_
80-6	14105-14108	and	_
80-7	14109-14117	Clinical	_
80-8	14118-14127	Variables	_
80-9	14128-14132	Next	_
80-10	14133-14134	,	_
80-11	14135-14137	we	_
80-12	14138-14146	examined	_
80-13	14147-14154	whether	_
80-14	14155-14160	there	_
80-15	14161-14165	were	_
80-16	14166-14178	associations	_
80-17	14179-14186	between	_
80-18	14187-14199	connectivity	_
80-19	14200-14211	impairments	_
80-20	14212-14215	and	_
80-21	14216-14220	both	_
80-22	14221-14230	cognitive	_
80-23	14231-14241	impairment	_
80-24	14242-14245	and	_
80-25	14246-14254	symptoms	_
80-26	14255-14256	(	_
80-27	14257-14260	and	_
80-28	14261-14273	specifically	_
80-29	14274-14282	positive	_
80-30	14283-14292	psychotic	_
80-31	14293-14301	symptoms	_
80-32	14302-14303	)	_
80-33	14304-14305	,	_
80-34	14306-14308	as	_
80-35	14309-14312	has	_
80-36	14313-14317	been	_
80-37	14318-14323	found	_
80-38	14324-14326	in	_
80-39	14327-14335	previous	_
80-40	14336-14344	research	_
80-41	14345-14346	.	_

81-1	14347-14349	To	_
81-2	14350-14354	test	_
81-3	14355-14360	these	_
81-4	14361-14371	hypotheses	_
81-5	14372-14373	,	_
81-6	14374-14376	we	_
81-7	14377-14385	examined	_
81-8	14386-14393	whether	_
81-9	14394-14399	there	_
81-10	14400-14404	were	_
81-11	14405-14416	significant	_
81-12	14417-14429	associations	_
81-13	14430-14437	between	_
81-14	14438-14442	each	_
81-15	14443-14454	significant	_
81-16	14455-14471	cortico-striatal	_
81-17	14472-14484	connectivity	_
81-18	14485-14492	finding	_
81-19	14493-14496	and	_
81-20	14497-14501	both	_
81-21	14502-14511	cognitive	_
81-22	14512-14522	impairment	_
81-23	14523-14525	on	_
81-24	14526-14529	the	_
81-25	14530-14534	SCIP	_
81-26	14535-14538	and	_
81-27	14539-14544	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
81-28	14545-14553	symptoms	_
81-29	14554-14555	.	_

82-1	14556-14561	These	_
82-2	14562-14573	regressions	_
82-3	14574-14582	included	_
82-4	14583-14586	the	_
82-5	14587-14596	following	_
82-6	14597-14607	predictors	_
82-7	14608-14609	:	_
82-8	14610-14613	sex	_
82-9	14614-14615	,	_
82-10	14616-14619	age	_
82-11	14620-14621	,	_
82-12	14622-14632	diagnostic	_
82-13	14633-14638	group	_
82-14	14639-14640	(	_
82-15	14641-14645	i.e.	_
82-16	14646-14647	,	_
82-17	14648-14655	healthy	_
82-18	14656-14664	subjects	_
82-19	14665-14666	,	_
82-20	14667-14680	schizophrenia	_
82-21	14681-14682	,	_
82-22	14683-14692	psychotic	_
82-23	14693-14700	bipolar	_
82-24	14701-14709	disorder	_
82-25	14710-14711	)	_
82-26	14712-14713	,	_
82-27	14714-14717	the	_
82-28	14718-14726	variable	_
82-29	14727-14729	of	_
82-30	14730-14738	interest	_
82-31	14739-14740	(	_
82-32	14741-14745	e.g.	_
82-33	14746-14747	,	_
82-34	14748-14752	SCIP	_
82-35	14753-14754	“	_
82-36	14755-14764	composite	_
82-37	14765-14766	”	_
82-38	14767-14774	z-score	_
82-39	14775-14776	)	_
82-40	14777-14778	,	_
82-41	14779-14782	and	_
82-42	14783-14785	an	_
82-43	14786-14797	interaction	_
82-44	14798-14805	between	_
82-45	14806-14816	diagnostic	_
82-46	14817-14822	group	_
82-47	14823-14826	and	_
82-48	14827-14830	the	_
82-49	14831-14839	variable	_
82-50	14840-14842	of	_
82-51	14843-14851	interest	_
82-52	14852-14853	.	_

83-1	14854-14857	For	_
83-2	14858-14861	the	_
83-3	14862-14868	cortex	_
83-4	14869-14879	seed-based	_
83-5	14880-14883	ROI	_
83-6	14884-14892	analysis	_
83-7	14893-14902	described	_
83-8	14903-14908	above	_
83-9	14909-14910	,	_
83-10	14911-14918	overall	_
83-11	14919-14931	connectivity	_
83-12	14932-14939	between	_
83-13	14940-14944	each	_
83-14	14945-14953	cortical	_
83-15	14954-14961	network	_
83-16	14962-14965	and	_
83-17	14966-14969	the	_
83-18	14970-14978	striatum	_
83-19	14979-14985	served	_
83-20	14986-14988	as	_
83-21	14989-14992	the	_
83-22	14993-15002	dependent	_
83-23	15003-15011	variable	_
83-24	15012-15014	in	_
83-25	15015-15025	regression	_
83-26	15026-15034	analyses	_
83-27	15035-15036	.	_

84-1	15037-15040	For	_
84-2	15041-15044	the	_
84-3	15045-15055	voxel-wise	_
84-4	15056-15064	analyses	_
84-5	15065-15066	,	_
84-6	15067-15071	mean	_
84-7	15072-15082	functional	_
84-8	15083-15095	connectivity	_
84-9	15096-15099	was	_
84-10	15100-15109	extracted	_
84-11	15110-15114	from	_
84-12	15115-15118	the	_
84-13	15119-15127	clusters	_
84-14	15128-15132	that	_
84-15	15133-15141	survived	_
84-16	15142-15154	thresholding	_
84-17	15155-15160	using	_
84-18	15161-15164	the	_
84-19	15165-15177	eigenvariate	_
84-20	15178-15186	function	_
84-21	15187-15189	in	_
84-22	15190-15195	SPM12	_
84-23	15196-15199	and	_
84-24	15200-15204	this	_
84-25	15205-15211	served	_
84-26	15212-15214	as	_
84-27	15215-15218	the	_
84-28	15219-15228	dependent	_
84-29	15229-15237	variable	_
84-30	15238-15240	in	_
84-31	15241-15251	regression	_
84-32	15252-15260	analyses	_
84-33	15261-15262	.	_

85-1	15263-15273	Regression	_
85-2	15274-15282	analyses	_
85-3	15283-15287	were	_
85-4	15288-15297	corrected	_
85-5	15298-15301	for	_
85-6	15302-15310	multiple	_
85-7	15311-15322	comparisons	_
85-8	15323-15324	(	_
85-9	15325-15330	using	_
85-10	15331-15336	False	_
85-11	15337-15346	Discovery	_
85-12	15347-15351	Rate	_
85-13	15352-15353	(	_
85-14	15354-15357	FDR	_
85-15	15358-15359	)	_
85-16	15360-15370	correction	_
85-17	15371-15372	)	_
85-18	15373-15378	based	_
85-19	15379-15381	on	_
85-20	15382-15385	the	_
85-21	15386-15392	number	_
85-22	15393-15395	of	_
85-23	15396-15408	associations	_
85-24	15409-15417	examined	_
85-25	15418-15419	(	_
85-26	15420-15424	i.e.	_
85-27	15425-15426	,	_
85-28	15427-15440	FDR-corrected	_
85-29	15441-15444	for	_
85-30	15445-15450	every	_
85-31	15451-15460	cognitive	_
85-32	15461-15471	impairment	_
85-33	15472-15475	and	_
85-34	15476-15483	symptom	_
85-35	15484-15492	variable	_
85-36	15493-15495	of	_
85-37	15496-15504	interest	_
85-38	15505-15508	for	_
85-39	15509-15510	a	_
85-40	15511-15516	total	_
85-41	15517-15519	of	_
85-42	15520-15524	four	_
85-43	15525-15538	FDR-corrected	_
85-44	15539-15550	comparisons	_
85-45	15551-15552	)	_
85-46	15553-15556	for	_
85-47	15557-15561	each	_
85-48	15562-15573	significant	_
85-49	15574-15590	cortico-striatal	_
85-50	15591-15603	connectivity	_
85-51	15604-15611	finding	_
85-52	15612-15613	.	_

